While the immune response mostly has been investigated in the context of ER‐negative or HER2‐positive breast cancer were higher expression often has been associated with better survival and reduced metastatic risk,28, 43 it has also been associated with better pathologic complete response (pCR) in ER‐positive/HER2‐negative patients.29 Here, ERBB2 is linked to breast carcinoma.